GLENMARK · Glenmark Pharmaceuticals Ltd · Biotechnology & Drugs
GLENMARK · Glenmark Pharmaceuticals Ltd · Biotechnology & Drugs
As of 05 Nov close
52-week range
2.4% below 52-week high
52-week range: as of 05 Nov 2026 close.
Price chartDaily closes on the stock page.
Weighted combination of 8 measured readings. Not a probability, a rating or a forecast.
Full signal detail →Fundamentals as of 15 Sep 2026 · the company's own latest record is 52 days old
Revenue (latest Q)
₹4,018 Cr
Revenue YoY
PAT YoY
+930.3%
Operating margin
Revenue, last 8 quarters
P/E (TTM)
P/B
8.5
P/S (TTM)
3.9
Sector P/E
36.3
Dividend yield
+0.2%
| Company | P/E | P/B | Net margin | ROE | D/E | Div. yield |
|---|---|---|---|---|---|---|
| GLENMARK (this stock) | 34.6 | 8.5 | +10.1% | +17.1% | 0.06 | +0.2% |
| Sun Pharmaceutical Industries | 38.4 | 5.6 | +19.1% | +14.2% | 0.47 | +0.8% |
| Divi's Laboratories | 59.7 | 14.5 | +26.1% | +17.4% | 0 | +0.3% |
| Torrent Pharmaceuticals | 72.7 | 19.2 | +15.3% | +27.1% | 141.16 | +0.8% |
Promoter
stable
FII
rising 2q
MF
16.76% (-0.04pp)
stable
Insider trades
No insider trades in the last 12 months.
Bulk/block deals
No bulk/block deals in the last 12 months.
News timeline
- lowzerodha.com· 30 Sept 2026, 08:56 amAdditional exposure margin on securities under MWPL
- unknownprweb.com· 17 Sept 2026, 04:30 pmCareTria Launches RYALTRIS® Direct, Expanding Patient Access Through Pharmacy, Telesales, and Sampling Support
- unknowneconomictimes.indiatimes.com· 11 Sept 2026, 01:14 pmJioBlackRock Flexi Cap Fund exits NALCO, Hindustan Zinc; trims exposure in BSE, RIL
- unknowntimesofindia.indiatimes.com· 31 Aug 2026, 12:51 pmStocks to buy: What's the outlook for Nifty for August 31-September 4 week? Check list of top stock recommendations
- unknownzerodha.com· 26 Aug 2026, 09:01 amAdditional exposure margin on securities under MWPL
- mediumcorporate actioneconomictimes.indiatimes.com· 15 Jul 2026, 06:36 pmWarburg Pincus buys Mumbai’s pharma company Integrace in ₹1,200 crore deal
Concalls & investor presentations
AI-generatedKey takeaway: Glenmark Pharmaceuticals Limited submitted a letter to the National Stock Exchange of India and BSE Limited on August 5, 2026, regarding the transcript of their earnings call held on August 3, 2026. The earnings call discussed the company's performance for the quarter ended June 30, 2026. The transcript has been made available on the company's website for public access. The communication was signed by Rashmi Khandelwal, the Company Secretary and Compliance Officer.
The document presented factual information regarding the earnings call and its transcript.
Sourced from an exchange-filed transcript, dated 05 Aug 2026. Summary is RedixFi-generated and distinct from investment advice.
Key takeaway: Glenmark Pharmaceuticals Limited communicated the details of its Investor Day Presentation scheduled for June 9, 2026. The presentation outlined the company's strategic focus on becoming a leading, research-led global pharmaceutical entity, emphasizing its differentiated global platform for long-term value creation. Management reported a consolidated revenue of approximately US$2 billion and highlighted a strong presence in over 80 countries with a workforce of around 17,000 employees. The agenda included discussions on scaling global growth engines, creating long-term shareholder value, and advancing innovation in next-generation biologics. Management set a goal of achieving a 10-12% revenue growth over the next few years and emphasized the importance of expanding its branded business, particularly in key therapeutic areas such as oncology and respiratory. The document also addressed potential risks and ongoing mitigations related to macroeconomic challenges and competition in the pharmaceutical industry.
The presentation provided a balanced overview of the company's strategies and goals without overly optimistic or pessimistic language.
Sourced from an exchange-filed presentation, dated 09 Jun 2026. Summary is RedixFi-generated and distinct from investment advice.
Key takeaway: Glenmark Pharmaceuticals Limited reported consolidated revenue of Rs. 37,706 million for Q4 FY26, reflecting a year-on-year growth of 15.8%. The India business grew by 8.2%, while North America and Europe saw growth rates of 29.4% and 21.4%, respectively. The company's EBITDA was Rs. 7,626 million, with an EBITDA margin of 20.2%, and a profit after tax (PAT) of Rs. 3,013 million, resulting in a PAT margin of 7.6%. Chairman Glenn Saldanha highlighted FY26 as a defining year, noting strong business performance and strategic advancements, including a significant licensing deal with AbbVie for ISB 2001. The presentation detailed multiple product launches and expansions in various markets, emphasizing Glenmark's commitment to innovation and growth in the pharmaceutical sector.
Management highlighted strong business performance and strategic advancements.
Sourced from an exchange-filed presentation, dated 29 May 2026. Summary is RedixFi-generated and distinct from investment advice.
Key takeaway: Glenmark Pharmaceuticals Limited submitted a transcript of its earnings call held on February 2, 2026, regarding the third quarter and nine months ended December 31, 2025. The document was uploaded to the company's website and is in compliance with SEBI regulations. The communication was signed by Harish Kuber, the Company Secretary and Compliance Officer, and included contact information for the company. The letter was addressed to the Manager of Listing at the National Stock Exchange of India and BSE Ltd.
The document presented factual information regarding the submission of the earnings call transcript.
Sourced from an exchange-filed transcript, dated 04 Feb 2026. Summary is RedixFi-generated and distinct from investment advice.
AI Summary of Annual Report
AI-generatedGlenmark Pharmaceuticals Limited's FY2025-26 Integrated Annual Report highlights the company's strategic focus on sustainable value creation, governance, and business model resilience. The report outlines the company's adherence to global reporting standards like GRI, TCFD, and TNFD, and its alignment with the UN SDGs. The pharmaceutical industry faces challenges such as geopolitical tensions, supply chain complexities, and pricing pressures, but is expected to benefit from AI-driven productivity and growing demand for medicines. The company emphasizes its commitment to stakeholder engagement, risk management, and compliance with statutory and regulatory requirements. No material non-compliance or defaults were reported, and the company has not faced any significant legal or regulatory actions that impact its going-concern status.
- The report is prepared in accordance with the International Integrated Reporting <IR> Framework, providing a holistic view of the company's strategy, governance, business model, performance, and outlook.
- Glenmark has aligned its sustainability reporting with global standards including TCFD, TNFD, and the UN SDGs, reflecting its commitment to responsible business practices.
- The pharmaceutical industry is navigating challenges like geopolitical tensions, supply chain complexities, and pricing pressures, but is expected to benefit from AI-driven productivity and growing demand for medicines.
- No material non-compliance, defaults, or significant legal actions were reported, and the company has not faced any proceedings under the Insolvency and Bankruptcy Code, 2016.
Key takeaway: Glenmark Pharmaceuticals Limited demonstrates a strong commitment to integrated reporting, sustainability, and compliance, while navigating industry-wide challenges with a focus on innovation and operational efficiency.
The following annual report excerpts provide qualitative strategic context. Do not treat any specific financial figures in these excerpts as authoritative — they may be incorrectly labeled due to PDF table extraction limitations. For precise financial data, refer to the structured fundamentals data above.
Governance disclosures
AI-generatedNeeds attention
Regulatory Action (3 items)
Items of these kinds are disclosed in the filings. This is a count of disclosed items. It is not a finding about the company and its cause has not been independently established.
Regulatory Action
3 occurrencesRecent (last 12 months)
In October 2019, NPPA issued a Show Cause Notice to Glenmark Pharmaceuticals Limited for alleged violation of DPCO 2013 by self-invoking Para 32 for its product Remogliflozin Etabonate + Metformin. The company challenged this in Delhi High Court, which ordered NPPA to grant a hearing on the matter without enforcing the impugned orders.
Earlier (1-3 years ago)
In October 2019, NPPA issued a Show Cause Notice alleging the company violated DPCO 2013 by self-invoking Para 32 for its product Remogliflozin Etabonate + Metformin Hydrocloride without seeking government exemption approval. The company challenged this in Delhi High Court, but NPPA issued a ceiling price notification in March 2020 without resolving the entitlement under Para 32.
The company is involved in a regulatory dispute with NPPA regarding alleged violations of DPCO 2013, with a show cause notice issued and legal proceedings ongoing.
Routine disclosures
Internal Control Weakness
1 occurrenceEarlier (1-3 years ago)
The auditor mentions evaluating internal controls and communicating with governance about significant deficiencies.
Contingent Liability
3 occurrencesRecent (last 12 months)
The company is involved in various legal proceedings including product liability, contracts, employment claims, and other regulatory matters. The amounts involved are material and are accounted for under Ind AS 37 for provisions, contingent liabilities, and contingent assets.
Earlier (1-3 years ago)
Glenmark Pharmaceuticals Limited has pending litigations with various direct tax, indirect tax and other authorities as of 31 March 2025.
The company is involved in various legal proceedings including product liability, contracts, employment claims and other regulatory matters. The outcome of these litigations is uncertain and could significantly impact the company's reported results and balance sheet position.
Related-Party Transaction
1 occurrenceRecent (last 12 months)
The company has disclosed transactions with entities over which Key Management Personnel exercise significant influence, including contributions to CSR activities and various sales, purchases, and loans with related parties such as Glenmark Pharmaceuticals Inc., Glenmark Impex L.L.C., and Glenmark Pharmaceuticals S.R.O.
Statutory dues in dispute
2 occurrencesRecent (last 12 months)
The company has disputes over income tax and goods and services tax dues, with amounts unpaid and pending resolution in various forums including High Court and tribunals.
Earlier (1-3 years ago)
The company has outstanding statutory dues related to Income Tax, Service Tax, Excise Duty, and GST for various fiscal years, with disputes pending before authorities such as the Supreme Court, High Court, and CESTAT.
Promoter Share Pledge
1 occurrenceRecent (last 12 months)
1.32% of promoter holding pledged (quarter 2026-Q3 as of 2026-07-18).